Here’s What you Should Know About Inclining Premarket Stock of Aptorum Group Ltd. (APM)

Related Topics

Facebook
Twitter
LinkedIn
WhatsApp

Aptorum Group Ltd. (APM) is a leading biotherapeutics company. It is engaged in the development and commercialization of treatments for oncology and infectious diseases. The company also focuses on its therapeutics platform for gastro and metabolic issues along with women’s health.

The price of APM stock during the regular trading on January 24, 2022 was $1.62 with 9.46% incline. At last check in the premarket on January 25, 2022, the stock further rocketed by 42.5%.

APM: Events and Happenings

On January 20, 2022, APM reported about the grant of Orphan Drug Designation to SACT-1 by FDA. It is utilized in treating patients with Neuroblastoma. The company is also expecting to file IND application to commence phase 1/2 studies. On January 18, 2022, APM reported about the grant of preliminary patent status for the SACT-1 by the US Patent and Trademark Office.

APM on January 10, 2022, reported that its subsidiary had commenced the clinical authentication of its rapid pathogen diagnostics liquid biopsy technology for diagnosing the pathogens. On January 10, 2022, APM reported about initiation of its cancer and autoimmune development portfolio. On January 10, 2022, APM reported about closure of clinical trials for ALS-4 and evaluating the relative bioavailability and food impact of SACT-1.

APM on December 3, 2021, reported about the outcomes of 2021 annual general meeting of stockholders held on December 2. The stockholders re-elected all the current management of the company. Along with approving the re-appointment of company’s independent auditors, the stockholders also approved amendments to different articles.

APM: Key Financials

On September 15, 2021, APM reported its financial results for the six months ended June 30, 2021. Some of the key updates are as follows.

Net Loss per Share

Basic and diluted net loss per share in H1 2021 was $17.1 million or $0.47 compared to $7.0 million or $0.21 for the same period in 2020.

Assets

Total current assets of the company in first half of 2021 were $21.9 million.

Conclusion

APM stock is 39% down the past half yearly period due to the economic restrictions imposed by the global pandemic. The current premarket surge in stock is the result of uncertain reasons as the company has not reported any recent news regarding its activities. The financial specialists are expecting more accomplishments from the company in the coming days.

Leave a Comment

Your email address will not be published.

Latest Posts